CoRycardon^® has been launched in the Cyprus in the beginning of the current year (January 2011).

This product is a valuable addition to AEGIS’ Cardiovascular and Metabolism (CVM) portfolio. CoRycardon^® is used in the treatment of essential hypertension;

CoRycardon^® is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.

For further therapeutic information please consult the Summary of  Product Characteristics (SPC).

SPC CoRYCARDON^®